Premium
Cathepsin‐B Induced Controlled Release from Peptide‐Capped Mesoporous Silica Nanoparticles
Author(s) -
de la Torre Cristina,
Mondragón Laura,
Coll Carmen,
Sancenón Félix,
Marcos María D.,
MartínezMáñez Ramón,
Amorós Pedro,
PérezPayá Enrique,
Orzáez Mar
Publication year - 2014
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201404382
Subject(s) - cathepsin b , peptide , doxorubicin , mesoporous silica , hela , cathepsin l , cathepsin d , chemistry , internalization , microbiology and biotechnology , in vitro , biochemistry , cathepsin , enzyme , mesoporous material , cell , biology , chemotherapy , genetics , catalysis
New capped silica mesoporous nanoparticles for intracellular controlled cargo release within cathepsin B expressing cells are described. Nanometric mesoporous MCM‐41 supports loaded with safranin O ( S1‐P ) or doxorubicin ( S2‐P ) containing a molecular gate based on a cathepsin B target peptidic sequence were synthesized. Solids were designed to show “zero delivery” and to display cargo release in the presence of cathepsin B enzyme, which selectively hydrolyzed in vitro the capping peptide sequence. Controlled delivery in HeLa, MEFs WT, and MEFs lacking cathepsin B cell lines were also tested. Release of safranin O and doxorubicin in these cells took place when cathepsin B was active or present. Cells treated with S2‐P showed a fall in cell viability due to nanoparticles internalization, cathepsin B hydrolysis of the capping peptide, and cytotoxic agent delivery, proving the possible use of these nanodevices as new therapeutic tools for cancer treatment.